FUJIFILM Diosynth Biotechnologies  

Morrisville,  NC 
United States
http://www.fujifilmdiosynth.com

• Booth: 420

Stop by booth #420 and meet with our team to learn more.

FUJIFILM Diosynth Biotechnologies is an industry-leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting the biopharmaceutical industry in the development and production of biologics, vaccines and advanced therapies.

Our focus is to combine technical leadership in process development and cGMP manufacturing supported by a strong team of over 4,000 employees and a reputation for excellent customer service. We are a trusted partner of many clients, from early stage biotechs to large pharma.

Our locations:

• Watertown and Cambridge, MA
• Research Triangle Park, NC
• Holly Springs, NC, USA (coming in 2024)
• College Station, TX
• Hillerød, Denmark
• Teesside, UK
• Thousand Oaks, CA

Key Service Areas:

• Cell Culture
• Microbial Fermentation 
• Advanced Therapies
• Drug Product Manufacturing
• Finished Goods
• CMC Support Services

 Videos

 Press Releases

• Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. (May 06, 2022)
  https://fujifilmdiosynth.com/about-us/press-releases/fujifilm-completes-acquisition-of-a-dedicated-cell-therapy-manufacturing-facility-from-atara-biotherapeutics-inc/

• Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. (May 06, 2022)
  https://fujifilmdiosynth.com/about-us/press-releases/fujifilm-expands-its-advanced-therapies-cdmo-business-with-the-acquisition-of-a-dedicated-cell-therapy-manufacturing-facility-from-atara-biotherapeutics-inc/

• FUJIFILM Diosynth Biotechnologies to Increase Advanced Therapy and Vaccine Production Capacity with New $300 Million Facility in Texas (May 06, 2022)
  https://fujifilmdiosynth.com/about-us/press-releases/fujifilm-diosynth-biotechnologies-to-increase-advanced-therapy-and-vaccine-production-capacity-with-new-300-million-facility-in-texas/

• FUJIFILM Diosynth Biotechnologies confirms £400 million investment plans to create the largest multi-modal biopharmaceutical manufacturing site in the United Kingdom (May 06, 2022)
  https://fujifilmdiosynth.com/about-us/press-releases/fujifilm-diosynth-biotechnologies-confirms-400-million-investment-plans-to-create-the-largest-multi-modal-biopharmaceutical-manufacturing-site-in-the-united-kingdom/

• FUJIFILM DIOSYNTH BIOTECHNOLOGIES BREAKS GROUND ON THE LARGEST CELL CULTURE BIOPHARMACEUTICAL CDMO FACILITY IN NORTH AMERICA (May 06, 2022)
  https://fujifilmdiosynth.com/about-us/press-releases/fujifilm-diosynth-biotechnolgogies-breaks-ground-on-the-largest-cell-culture-biopharmaceutical-cdmo-facility-in-north-america/